Healthcare billing isn’t the headline-grabber in tech, but when providers lose millions because insurers weaponize denials, it suddenly feels like the only story that matters. XiFin, Inc. has been locked into that problem since 1997, long before “SaaS” was investor catnip and way before “AI” became every pitch deck’s closing argument. Founded by Lâle White, who went from VP of Finance at LabCorp to building a company designed to turn inefficiency into opportunity, XiFin understood early that cash flow is the bloodstream of healthcare. If it clogs, the body dies.
Now XiFin is reloaded with fresh growth funding led by Goldman Sachs External Investing Group, backed by Avista Healthcare Partners and other institutional investors. The exact number is under wraps, but the message is obvious: capital doesn’t chase hype, it chases traction. XiFin Empower isn’t some shiny dashboard dressed up in today. It’s a full-stack RCM engine, claims, coding, denials, payments, analytics, that already keeps revenue intact for eleven of the fifteen largest public labs, four of the top five integrated delivery networks, and more than thirty thousand retail pharmacies.
The leadership roster makes the story even tighter. Lâle White is still running point as Executive Chairman and CEO. Jeffrey Yates drives technology as CTO. Mike Coats builds product. Kyle Fetter handles operations. Erik Sallee commands finance. Harley Ross grows the business. Lee Ann Nichols locks down customer success. Add Jeffrey Margolis, ex-CEO of TriZetto and one of the sharper minds in healthcare IT, to the board, and you’ve got a table where investors don’t just bring checks, they bring conviction.
This raise isn’t about vanity expansion. It’s about pushing AI and machine learning deeper into workflows that bleed time and cash. Predictive cash-flow forecasting. Patient engagement tools that actually align with value-based care. Smarter denials management in markets where specialty pharmacy and diagnostics run the most complex billing imaginable. It’s technical, it’s messy, and it’s the kind of problem that XiFin has been solving before anyone called it “transformational.”
Huge news for Lâle White, Jeffrey Yates, Mike Coats, and the entire XiFin team. Goldman Sachs External Investing Group and Avista Healthcare Partners didn’t just invest in a platform. They invested in the rails that move healthcare money faster, cleaner, and more intelligently. In a market set to surge past seventy billion by 2030, that looks less like a funding round and more like inevitability.
